ClinicalTrials.gg
RecruitingNCT04807660Updated Oct 29, 2026

Bacteriological Evaluation of Children With Otorrhea

An observational study in Otorrhea, sponsored by Association Clinique Thérapeutique Infantile du val de Marne. Recruiting at 1 site in France. Open to participants aged 3 Months to 15 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Association Clinique Thérapeutique Infantile du val de Marne · Observational

How we know

From the registry’s dates

  • Started Oct 2015; still recruiting 11 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,500
Ages
3 Months to 15 Years
Sex
All
01

Study summary

After pneumococcal conjugate vaccine implementation, the number of acute otitis media (AOM) episodes has decreased, but AOM still remains among the most common diagnoses in childhood. From 2% to 17% of cases of AOM feature spontaneous perforation of the tympanic membrane (SPTM). The aim of this study was to describe the bacteriological causes of SPTM several years after PCV13 implementation, in 2010.

Read the detailed description

Since October 2015, children with spontaneous perforation of the tympanic membrane (SPTM) are prospectively enrolled by 20 pediatricians who are part of a research and teaching network (ACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne [Clinical and Therapeutic Association of Val de Marne]) throughout France. For some patients, otorrhea is the first manifestation of AOM; for others, otorrhea occurred after AOM treatment failure or recurrence. Failure (non-responsive AOM) is defined as otorrhea appearing despite at least 48 hr of antibiotics or recurring less than 4 days after the end of antibiotic treatment. Recurrence is defined by the appearance of otorrhea 4 to 30 days after the end of antibiotic treatment for AOM.

Middle ear fluid (MEF) is obtained by sampling spontaneous discharge according to clinical practice guidelines. MEF specimens are obtained with cotton-tipped wire swabs, immediately placed in transport medium (Copan Venturi Transystem®, Brescia, Italy), and transported within 48 hr to one of the two centralized microbiology laboratories (Robert Debré Hospital or National Centre for Pneumococci at European Georges Pompidou Hospital, Paris, France).

02

Conditions studied

  • Otorrhea

Keywords

  • otorrhea
  • children
  • spontaneous perforation of the tympanic membrane
  • ambulatory
  • streptococcus pneumoniae
  • heamophilus influenzae
  • moraxella catarrhalis
  • streptococcus pyogenes
03

In context

Lead sponsor

Association Clinique Thérapeutique Infantile du val de Marne is the lead sponsor of 15 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

all children from 3 months to 15 years old with otorrhea

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children from 3 months to 15 years old
  • with otorrhea
  • signed parents consent

Exclusion criteria

Exclusion Criteria:

  • children under 3 months
  • children > 15 years old
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective cohort

    Middle ear fluid sample for each enrrolled children

    Other: middle ear fluid sample for bacterial analysis (conventional microbiology analysis)

Interventions

  • Othermiddle ear fluid sample for bacterial analysis (conventional microbiology analysis)

    A middle ear fluid sample will be collected from each enrolled child for the third analysis procedure.

    Also known as: middle ear fluid sample for molecular sequencing analysis, middle ear fluid sample for Rapid Diagnostic Test (RDT)

06

What researchers measure

Primary outcomes

  1. Microbiological Profiles of Spontaneous Otorrhea in Children

    To determine the microbiological profiles of spontaneous otorrhea in children by identifying the bacterial pathogens present in collected samples.

    Time frame: at inclusion

Secondary outcomes

  1. Descriptive analysis of patient characteristics according to bacteriological Profiles

    To describe, for each bacterial species identified, patient characteristics according to demographics, vaccinal and general medical history, AOM history, and sample collection conditions.

    Time frame: at inclusion

  2. Clinical Characteristics of Treatment Failure or Recurrence in Children with AOM

    To describe the clinical characteristics of treatment failure or recurrence in children with acute otitis media (AOM), according to the identified bacteria, including symptom severity, duration, and observed clinical signs.

    Time frame: at inclusion

  3. Microbiota Analysis of Spontaneous Otorrhea in Children

    To analyze the microbiota involved in spontaneous otorrhea and bacterial interactions using molecular biology techniques and compare these results with conventional bacteriological methods.

    Time frame: at inclusion

  4. Comparison Between Rapid Diagnostic Test (RDT) and Laboratory Results

    To compare the results of the rapid diagnostic test (RDT) with those obtained from samples analyzed in the laboratory using standard bacteriological methods.

    Time frame: at inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Levy C, Varon E, Ouldali N, Wollner A, Thollot F, Corrard F, Werner A, Bechet S, Bonacorsi S, Cohen R. Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine. PLoS One. 2019 Feb 1;14(2):e0211712. doi: 10.1371/journal.pone.0211712. eCollection 2019. PubMed 30707730 ↗
  • Assad Z, Cohen R, Varon E, Levy C, Bechet S, Corrard F, Werner A, Ouldali N, Bonacorsi S, Rybak A. Antibiotic Resistance of Haemophilus influenzae in Nasopharyngeal Carriage of Children with Acute Otitis Media and in Middle Ear Fluid from Otorrhea. Antibiotics (Basel). 2023 Nov 8;12(11):1605. doi: 10.3390/antibiotics12111605. PubMed 37998807 ↗
  • Levy C, Varon E, Bidet P, Bechet S, Batard C, Wollner A, Thollot F, Bonacorsi S, Cohen R. Otorrhea bacterial profile, epidemiology before widespread use of the third-generation pneumococcal conjugate vaccine in French children, a prospective study from 2015 to 2023. Infect Dis Now. 2023 Sep;53(6):104738. doi: 10.1016/j.idnow.2023.104738. Epub 2023 Jun 17. PubMed 37331698 ↗
  • Cohen R, Varon E, Bidet P, Cohen JF, Bechet S, Couloigner V, Michot AS, Guiheneuf C, Bonacorsi S, Levy C. Diagnostic Accuracy of Group A Streptococcus Rapid Antigen Detection Test on Middle Ear Fluid in Children With Acute Otitis Media With Spontaneous Perforation: A Prospective Multicenter Evaluation. Pediatr Infect Dis J. 2023 Sep 1;42(9):816-818. doi: 10.1097/INF.0000000000004009. Epub 2023 Jun 22. PubMed 37368992 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2015 (actual). Primary completion is estimated for Oct 2028, 156 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
Mar 19, 2021
StartActual
Oct 1, 2015
Primary completionEst.
Oct 31, 2028
CompletionEst.
Oct 31, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and references
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04807660
Lead sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Oct 1, 2015
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Corinne Levy, MD
Contact
corinne.levy@activ-france.fr
0033148850404
Stéphane Béchet, MSc
Contact
sgtephane.bechet@activ-france.fr
0033148850404
Robert Cohen
study director · Association Clinique et Thérapeutique Infantile du Val de Marne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion